McKenna Mark C.
Insider CIK 1749623 · SYRE Director · RXDX Chairman, President and CEO, Director · BBOT · NAMS Director · APGE Director · FRNM · BHC President, Salix
Trades across companies
| Ticker | Code | Trade | Filed | Shares | Price | Value | Owned after | |
|---|---|---|---|---|---|---|---|---|
| APGE Apogee Therapeutics, Inc. | D To issuer deriv | 2026-09-03 | 2026-09-03 | 10,370 | — | $0 | 0 | SEC↗ |
| APGE Apogee Therapeutics, Inc. | D To issuer deriv | 2026-09-03 | 2026-09-03 | 7,657 | — | $0 | 0 | SEC↗ |
| APGE Apogee Therapeutics, Inc. | D To issuer deriv | 2026-09-03 | 2026-09-03 | 150,000 | — | $0 | 0 | SEC↗ |
| APGE Apogee Therapeutics, Inc. | D To issuer deriv | 2026-09-03 | 2026-09-03 | 14,461 | — | $0 | 0 | SEC↗ |
| APGE Apogee Therapeutics, Inc. | D To issuer | 2026-09-03 | 2026-09-03 | 20,000 | — | $0 | 0 | SEC↗ |
| APGE Apogee Therapeutics, Inc. | D To issuer deriv | 2026-09-03 | 2026-09-03 | 7,657 | — | — | 0 | SEC↗ |
| APGE Apogee Therapeutics, Inc. | D To issuer deriv | 2026-09-03 | 2026-09-03 | 14,461 | — | — | 0 | SEC↗ |
| APGE Apogee Therapeutics, Inc. | D To issuer deriv | 2026-09-03 | 2026-09-03 | 10,370 | — | — | 0 | SEC↗ |
| APGE Apogee Therapeutics, Inc. | D To issuer deriv | 2026-09-03 | 2026-09-03 | 150,000 | — | — | 0 | SEC↗ |
| APGE Apogee Therapeutics, Inc. | D To issuer | 2026-09-03 | 2026-09-03 | 20,000 | — | — | 0 | SEC↗ |
| FRNM Freenome, Inc. | C Conversion deriv | 2026-07-20 | 2026-07-22 | 30,000 | — | $0 | 0 | SEC↗ |
| FRNM Freenome, Inc. | C Conversion | 2026-07-20 | 2026-07-22 | 30,000 | — | $0 | 30,000 | SEC↗ |
| APGE Apogee Therapeutics, Inc. | A Award deriv | 2026-06-09 | 2026-06-11 | 7,657 | — | $0 | 7,657 | SEC↗ |
| SYRE Spyre Therapeutics, Inc. | A Award deriv | 2026-05-27 | 2026-05-29 | 8,026 | — | $0 | 8,026 | SEC↗ |
| NAMS NewAmsterdam Pharma Co N.V | A Award deriv | 2026-01-07 | 2026-01-09 | 15,300 | — | $0 | 15,300 | SEC↗ |
| NAMS NewAmsterdam Pharma Co N.V | A Award | 2026-01-07 | 2026-01-09 | 3,400 | — | $0 | 10,360 | SEC↗ |
| BBOT BridgeBio Oncology Therape | M Exercise deriv | 2025-08-11 | 2025-08-11 | 30,000 | — | $0 | 0 | SEC↗ |
| BBOT BridgeBio Oncology Therape | M Exercise | 2025-08-11 | 2025-08-11 | 30,000 | — | $0 | 30,000 | SEC↗ |
| APGE Apogee Therapeutics, Inc. | A Award deriv | 2025-06-17 | 2025-06-20 | 14,461 | — | $0 | 14,461 | SEC↗ |
| SYRE Spyre Therapeutics, Inc. | A Award deriv | 2025-05-29 | 2025-06-02 | 25,000 | — | $0 | 25,000 | SEC↗ |
| NAMS NewAmsterdam Pharma Co N.V | A Award | 2025-01-07 | 2025-01-08 | 6,960 | — | $0 | 6,960 | SEC↗ |
| NAMS NewAmsterdam Pharma Co N.V | A Award deriv | 2025-01-06 | 2025-01-08 | 32,500 | — | $0 | 32,500 | SEC↗ |
| APGE Apogee Therapeutics, Inc. | P Buy | 2024-12-12 | 2024-12-16 | 7,500 | $49.02 | $367.6K | 7,500 | SEC↗ |
| APGE Apogee Therapeutics, Inc. | P Buy | 2024-12-12 | 2024-12-16 | 12,500 | $49.85 | $623.1K | 20,000 | SEC↗ |
| NAMS NewAmsterdam Pharma Co N.V | A Award deriv | 2024-07-17 | 2024-07-19 | 72,500 | — | $0 | 72,500 | SEC↗ |
| APGE Apogee Therapeutics, Inc. | A Award deriv | 2024-06-05 | 2024-06-07 | 10,370 | — | $0 | 10,370 | SEC↗ |
| SYRE Spyre Therapeutics, Inc. | A Award deriv | 2024-02-01 | 2024-02-05 | 40,000 | — | $0 | 40,000 | SEC↗ |
| APGE Apogee Therapeutics, Inc. | A Award deriv | 2023-08-17 | 2023-08-21 | 100,000 | — | $0 | 150,000 | SEC↗ |
| APGE Apogee Therapeutics, Inc. | A Award deriv | 2023-08-17 | 2023-08-21 | 50,000 | — | $0 | 50,000 | SEC↗ |
| RXDX Prometheus Biosciences, In | D To issuer deriv | 2023-06-16 | 2023-06-16 | 246,639 | — | $0 | 0 | SEC↗ |
| RXDX Prometheus Biosciences, In | D To issuer deriv | 2023-06-16 | 2023-06-16 | 290,000 | — | $0 | 0 | SEC↗ |
| RXDX Prometheus Biosciences, In | D To issuer deriv | 2023-06-16 | 2023-06-16 | 132,741 | — | $0 | 0 | SEC↗ |
| RXDX Prometheus Biosciences, In | D To issuer deriv | 2023-06-16 | 2023-06-16 | 128,930 | — | $0 | 0 | SEC↗ |
| RXDX Prometheus Biosciences, In | D To issuer deriv | 2023-06-16 | 2023-06-16 | 161,105 | — | $0 | 0 | SEC↗ |
| RXDX Prometheus Biosciences, In | D To issuer deriv | 2023-06-16 | 2023-06-16 | 20,000 | — | $0 | 0 | SEC↗ |
| RXDX Prometheus Biosciences, In | D To issuer deriv | 2023-06-16 | 2023-06-16 | 481,725 | — | $0 | 0 | SEC↗ |
| RXDX Prometheus Biosciences, In | D To issuer deriv | 2023-06-16 | 2023-06-16 | 566,307 | — | $0 | 0 | SEC↗ |
| RXDX Prometheus Biosciences, In | D To issuer | 2023-06-16 | 2023-06-16 | 178,098 | — | $0 | 0 | SEC↗ |
| RXDX Prometheus Biosciences, In | M Exercise deriv | 2023-06-02 | 2023-06-02 | 3 | — | $0 | 132,741 | SEC↗ |
| RXDX Prometheus Biosciences, In | M Exercise deriv | 2023-06-02 | 2023-06-02 | 122,528 | — | $0 | 161,105 | SEC↗ |
| RXDX Prometheus Biosciences, In | M Exercise | 2023-06-02 | 2023-06-02 | 122,528 | $2.90 | $355.3K | 177,672 | SEC↗ |
| RXDX Prometheus Biosciences, In | M Exercise | 2023-06-02 | 2023-06-02 | 3 | $1.70 | $5 | 178,036 | SEC↗ |
| RXDX Prometheus Biosciences, In | M Exercise deriv | 2023-03-15 | 2023-03-17 | 25,000 | — | $0 | 283,633 | SEC↗ |
| RXDX Prometheus Biosciences, In | M Exercise | 2023-03-15 | 2023-03-17 | 25,000 | $2.90 | $72.5K | 80,144 | SEC↗ |
| RXDX Prometheus Biosciences, In | S Sale | 2023-03-15 | 2023-03-17 | 25,000 | $116.14 | $2.90M | 55,144 | SEC↗ |
| RXDX Prometheus Biosciences, In | M Exercise deriv | 2023-03-03 | 2023-03-03 | 10,620 | — | $0 | 481,725 | SEC↗ |
| RXDX Prometheus Biosciences, In | M Exercise | 2023-03-03 | 2023-03-03 | 10,620 | $3.70 | $39.3K | 65,764 | SEC↗ |
| RXDX Prometheus Biosciences, In | S Sale | 2023-03-03 | 2023-03-03 | 10,620 | $125.13 | $1.33M | 55,144 | SEC↗ |
| RXDX Prometheus Biosciences, In | M Exercise deriv | 2023-03-01 | 2023-03-03 | 700 | — | $0 | 492,345 | SEC↗ |
| RXDX Prometheus Biosciences, In | M Exercise | 2023-03-01 | 2023-03-03 | 700 | $3.70 | $2.6K | 55,844 | SEC↗ |
| RXDX Prometheus Biosciences, In | S Sale | 2023-03-01 | 2023-03-03 | 700 | $125.26 | $87.7K | 55,144 | SEC↗ |
| RXDX Prometheus Biosciences, In | M Exercise deriv | 2023-02-17 | 2023-02-17 | 13,680 | — | $0 | 493,045 | SEC↗ |
| RXDX Prometheus Biosciences, In | S Sale | 2023-02-17 | 2023-02-17 | 13,680 | $125.10 | $1.71M | 55,144 | SEC↗ |
| RXDX Prometheus Biosciences, In | M Exercise | 2023-02-17 | 2023-02-17 | 13,680 | $3.70 | $50.6K | 68,824 | SEC↗ |
| RXDX Prometheus Biosciences, In | M Exercise deriv | 2023-02-16 | 2023-02-17 | 25,000 | — | $0 | 506,725 | SEC↗ |
| RXDX Prometheus Biosciences, In | M Exercise | 2023-02-16 | 2023-02-17 | 25,000 | $3.70 | $92.5K | 80,144 | SEC↗ |
| RXDX Prometheus Biosciences, In | S Sale | 2023-02-16 | 2023-02-17 | 25,000 | $119.87 | $3.00M | 55,144 | SEC↗ |
| RXDX Prometheus Biosciences, In | M Exercise deriv | 2023-02-15 | 2023-02-17 | 25,000 | — | $0 | 308,633 | SEC↗ |
| RXDX Prometheus Biosciences, In | S Sale | 2023-02-15 | 2023-02-17 | 25,000 | $119.42 | $2.99M | 55,144 | SEC↗ |
| RXDX Prometheus Biosciences, In | M Exercise | 2023-02-15 | 2023-02-17 | 25,000 | $2.90 | $72.5K | 80,144 | SEC↗ |
| RXDX Prometheus Biosciences, In | M Exercise deriv | 2023-01-17 | 2023-01-19 | 25,000 | — | $0 | 333,633 | SEC↗ |
| RXDX Prometheus Biosciences, In | S Sale | 2023-01-17 | 2023-01-19 | 25,000 | $118.99 | $2.97M | 55,144 | SEC↗ |
| RXDX Prometheus Biosciences, In | M Exercise | 2023-01-17 | 2023-01-19 | 25,000 | $2.90 | $72.5K | 80,144 | SEC↗ |
| RXDX Prometheus Biosciences, In | A Award deriv | 2022-12-09 | 2022-12-13 | 128,930 | — | $0 | 128,930 | SEC↗ |
| RXDX Prometheus Biosciences, In | A Award | 2022-12-09 | 2022-12-13 | 37,113 | — | $0 | 55,144 | SEC↗ |
| RXDX Prometheus Biosciences, In | A Award deriv | 2022-05-20 | 2022-05-20 | 246,639 | — | $0 | 246,639 | SEC↗ |
| RXDX Prometheus Biosciences, In | M Exercise deriv | 2021-12-01 | 2021-12-03 | 15,400 | — | $0 | 122,531 | SEC↗ |
| RXDX Prometheus Biosciences, In | M Exercise | 2021-12-01 | 2021-12-03 | 15,400 | $2.90 | $44.7K | 15,400 | SEC↗ |
| RXDX Prometheus Biosciences, In | A Award deriv | 2021-11-14 | 2021-11-16 | 290,000 | — | $0 | 290,000 | SEC↗ |
| BHC Bausch Health Companies In | S Sale | 2019-08-19 | 2019-08-21 | 10,773 | $21.83 | $235.2K | 20,756 | SEC↗ |
| BHC Bausch Health Companies In | F Tax w/h | 2019-06-24 | 2019-06-26 | 1,913 | $23.82 | $45.6K | 31,529 | SEC↗ |
| BHC Bausch Health Companies In | F Tax w/h | 2019-05-06 | 2019-05-08 | 746 | $23.51 | $17.5K | 33,442 | SEC↗ |
| BHC Bausch Health Companies In | F Tax w/h | 2019-03-08 | 2019-03-12 | 974 | $23.56 | $22.9K | 34,188 | SEC↗ |
| BHC Bausch Health Companies In | A Award deriv | 2019-02-27 | 2019-03-01 | 44,290 | — | $0 | 44,290 | SEC↗ |
| BHC Bausch Health Companies In | A Award | 2019-02-27 | 2019-03-01 | 15,221 | — | $0 | 35,162 | SEC↗ |
| BHC Bausch Health Companies In | F Tax w/h | 2019-01-08 | 2019-01-10 | 1,190 | $21.25 | $25.3K | 19,941 | SEC↗ |